US FDA approves Journey Medical's drug for long-term skin condition
Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term ...
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people ...
MassDevice10h
NeurAxis wins expanded FDA clearance for non-implanted neurostim for pain relief
NeurAxis (NYSE:NRXS) announced today that the FDA granted an expanded 510(k) clearance for its IB-Stim non-implanted nerve ...
pirg13h
Pharma ads on social media are less regulated than you think
The rules we've established for pharma ads on TV and radio don't apply to ads on social media. That needs to change.
Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss?
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...
STAT19h
My son’s rare disease was renamed ASMD. Why are people still calling it Niemann-Pick?
Eponyms — diseases named after a person — can cause serious confusion. That is particularly true in one rare disease community.
EurekAlert!1d
ObesityWeek® research on Nov. 3 demonstrates gaps in drug labeling for people with obesity
SAN ANTONIO, Tx - Cancer patients need a lot of drugs—immunotherapies, chemotherapies, and anti-infectives. But new research at ObesityWeek® on Nov. 3, 2024, shows clinicians may not have all the ...
STAT3d
Lawsuit to fix pulse oximeter bias makes progress with device manufacturers
A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...
FiercePharma3d
'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...
FDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks
Pharmaceuticals announced the outcome of the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory ...
FiercePharma4d
UPDATED: FDA lists all doses of Novo's Wegovy as available, signaling potential end to semaglutide supply rout in US
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...